BMRN Q4 2024 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$747M+15.6% YoY

Gross Profit

$611M81.8% margin

Operating Income

$161M21.6% margin

Net Income

$125M16.7% margin

EPS (Diluted)

$0.64

QoQ Revenue Growth

+0.2%

Cash Flow

Operating Cash Flow

$186M

Free Cash Flow

$165M

Stock-Based Comp.

$52M

Balance Sheet

Total Assets

$7.0B

Total Liabilities

$1.3B

Stockholders' Equity

$5.7B

Cash & Equivalents

$943M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$747M	$646M	+15.6%
Gross Profit	$611M	$511M	+19.7%
Operating Income	$161M	$14M	+1035.2%
Net Income	$125M	$20M	+513.2%

Revenue Segments

Product

$736M98%

Royalty And Other

$12M2%